SE525461C3 - Ny användning av dextransulfat - Google Patents

Ny användning av dextransulfat

Info

Publication number
SE525461C3
SE525461C3 SE0203526A SE0203526A SE525461C3 SE 525461 C3 SE525461 C3 SE 525461C3 SE 0203526 A SE0203526 A SE 0203526A SE 0203526 A SE0203526 A SE 0203526A SE 525461 C3 SE525461 C3 SE 525461C3
Authority
SE
Sweden
Prior art keywords
cell
lmw
blood
dextran sulfate
dextran
Prior art date
Application number
SE0203526A
Other languages
English (en)
Swedish (sv)
Other versions
SE0203526D0 (sv
SE525461C2 (sv
SE0203526L (sv
Inventor
Bo Nilsson
Olle Korsgren
Original Assignee
Prophymed Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prophymed Ab filed Critical Prophymed Ab
Priority to SE0203526A priority Critical patent/SE525461C3/sv
Publication of SE0203526D0 publication Critical patent/SE0203526D0/xx
Priority to US10/535,876 priority patent/US8629123B2/en
Priority to DK03811973T priority patent/DK1567171T3/da
Priority to CNB2003801045438A priority patent/CN1296051C/zh
Priority to CA2507595A priority patent/CA2507595C/en
Priority to ES03811973T priority patent/ES2285270T3/es
Priority to JP2004555208A priority patent/JP4315908B2/ja
Priority to PT03811973T priority patent/PT1567171E/pt
Priority to NZ540744A priority patent/NZ540744A/en
Priority to EP03811973A priority patent/EP1567171B1/en
Priority to PL376302A priority patent/PL216067B1/pl
Priority to EA200500757A priority patent/EA010409B1/ru
Priority to BRPI0316666A priority patent/BRPI0316666B8/pt
Priority to DE60313356T priority patent/DE60313356T2/de
Priority to PCT/SE2003/001830 priority patent/WO2004047848A1/en
Priority to SI200330809T priority patent/SI1567171T1/sl
Priority to KR1020057009717A priority patent/KR100828807B1/ko
Priority to AU2003302378A priority patent/AU2003302378B2/en
Priority to AT03811973T priority patent/ATE359798T1/de
Publication of SE0203526L publication Critical patent/SE0203526L/xx
Publication of SE525461C2 publication Critical patent/SE525461C2/sv
Publication of SE525461C3 publication Critical patent/SE525461C3/sv
Priority to IL168626A priority patent/IL168626A/en
Priority to HR20050439A priority patent/HRP20050439B1/xx
Priority to ZA200504111A priority patent/ZA200504111B/en
Priority to NO20052505A priority patent/NO326946B1/no
Priority to IS7908A priority patent/IS2405B/is
Priority to HK06107463A priority patent/HK1087042A1/xx
Priority to CY20071100954T priority patent/CY1106739T1/el
Priority to JP2009064780A priority patent/JP4972113B2/ja
Priority to US12/685,005 priority patent/US8906884B2/en
Priority to US14/099,493 priority patent/US9364499B2/en
Priority to US14/099,518 priority patent/US8901104B2/en
Priority to US15/001,380 priority patent/US10307440B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/721—Dextrans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/39—Pancreas; Islets of Langerhans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
    • A61L27/3804—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
    • A61L27/3839—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by the site of application in the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/23—Carbohydrates
    • A61L2300/232—Monosaccharides, disaccharides, polysaccharides, lipopolysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/41—Anti-inflammatory agents, e.g. NSAIDs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/45—Mixtures of two or more drugs, e.g. synergistic mixtures
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
    • A61L2300/64—Animal cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Transplantation (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Botany (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Saccharide Compounds (AREA)
SE0203526A 2002-11-28 2002-11-28 Ny användning av dextransulfat SE525461C3 (sv)

Priority Applications (31)

Application Number Priority Date Filing Date Title
SE0203526A SE525461C3 (sv) 2002-11-28 2002-11-28 Ny användning av dextransulfat
NZ540744A NZ540744A (en) 2002-11-28 2003-11-26 Dextran sulphate used to treat Instant Blood-Mediated Inflammatory Reaction (IBMIR)
KR1020057009717A KR100828807B1 (ko) 2002-11-28 2003-11-26 새로운 용도의 덱스트란 설페이트
AT03811973T ATE359798T1 (de) 2002-11-28 2003-11-26 Verwendungvon dextransulfat zur behandlung von ibmir
CNB2003801045438A CN1296051C (zh) 2002-11-28 2003-11-26 糖酐酯的新用途
AU2003302378A AU2003302378B2 (en) 2002-11-28 2003-11-26 New use of dextran sulfate
ES03811973T ES2285270T3 (es) 2002-11-28 2003-11-26 Uso de sulfato de dextrano para tratar ibmir.
JP2004555208A JP4315908B2 (ja) 2002-11-28 2003-11-26 デキストラン硫酸エステルの新規用途
PT03811973T PT1567171E (pt) 2002-11-28 2003-11-26 Utilização de sulfato de dextrano para o tratamento de reacção inflamatória instantânea veiculada pelo sangue (riivs).
DK03811973T DK1567171T3 (da) 2002-11-28 2003-11-26 Anvendelse af dextransulfat til behandling af ibmir
EP03811973A EP1567171B1 (en) 2002-11-28 2003-11-26 Use of dextran sulfate for treating ibmir
PL376302A PL216067B1 (pl) 2002-11-28 2003-11-26 Zastosowanie siarczanu dekstranu
EA200500757A EA010409B1 (ru) 2002-11-28 2003-11-26 Применение декстрансульфата для ингибирования немедленной воспалительной реакции, опосредованной кровью
BRPI0316666A BRPI0316666B8 (pt) 2002-11-28 2003-11-26 novo uso de sulfato de dextrano
DE60313356T DE60313356T2 (de) 2002-11-28 2003-11-26 Verwendungvon dextransulfat zur behandlung von ibmir
PCT/SE2003/001830 WO2004047848A1 (en) 2002-11-28 2003-11-26 New use of dextran sulfate
SI200330809T SI1567171T1 (sl) 2002-11-28 2003-11-26 Uporaba dekstran sulfata za zdravljenje IBMIR
US10/535,876 US8629123B2 (en) 2002-11-28 2003-11-26 Use of dextran sulfate
CA2507595A CA2507595C (en) 2002-11-28 2003-11-26 Use of dextran sulfate in the treatment of instant blood-mediated inflammatory reaction
IL168626A IL168626A (en) 2002-11-28 2005-05-17 Use of dextran sulfate for the preparation of drugs for the treatment of IBMIR
HR20050439A HRP20050439B1 (en) 2002-11-28 2005-05-17 New use of dextran sulfate
ZA200504111A ZA200504111B (en) 2002-11-28 2005-05-20 New use of dexytran sulfate
NO20052505A NO326946B1 (no) 2002-11-28 2005-05-25 Anvendelse av dekstransulfat for behandling av IBMIR
IS7908A IS2405B (is) 2002-11-28 2005-06-23 Notkun dextransúlfats til að meðhöndla skyndilegtblóðmiðlað bólguviðbragð (IBMIR)
HK06107463A HK1087042A1 (en) 2002-11-28 2006-07-03 New use of dextran sulfate
CY20071100954T CY1106739T1 (el) 2002-11-28 2007-07-17 Χρηση του dextran sulfate (δεξτρανη θειικου αλατος) για θεραπεια της αμεσης αιμοκινουμενης φλεγμονωδους αντιδρασης
JP2009064780A JP4972113B2 (ja) 2002-11-28 2009-03-17 デキストラン硫酸エステルを含有する新規治療薬
US12/685,005 US8906884B2 (en) 2002-11-28 2010-01-11 Method of treating graft-rejection using dextran sulfate
US14/099,518 US8901104B2 (en) 2002-11-28 2013-12-06 Use of dextran sulfate
US14/099,493 US9364499B2 (en) 2002-11-28 2013-12-06 Use of dextran sulfate
US15/001,380 US10307440B2 (en) 2002-11-28 2016-01-20 Use of dextran sulfate

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0203526A SE525461C3 (sv) 2002-11-28 2002-11-28 Ny användning av dextransulfat

Publications (4)

Publication Number Publication Date
SE0203526D0 SE0203526D0 (sv) 2002-11-28
SE0203526L SE0203526L (sv) 2004-05-29
SE525461C2 SE525461C2 (sv) 2005-02-22
SE525461C3 true SE525461C3 (sv) 2005-03-23

Family

ID=20289705

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0203526A SE525461C3 (sv) 2002-11-28 2002-11-28 Ny användning av dextransulfat

Country Status (26)

Country Link
US (5) US8629123B2 (pl)
EP (1) EP1567171B1 (pl)
JP (2) JP4315908B2 (pl)
KR (1) KR100828807B1 (pl)
CN (1) CN1296051C (pl)
AT (1) ATE359798T1 (pl)
AU (1) AU2003302378B2 (pl)
BR (1) BRPI0316666B8 (pl)
CA (1) CA2507595C (pl)
CY (1) CY1106739T1 (pl)
DE (1) DE60313356T2 (pl)
DK (1) DK1567171T3 (pl)
EA (1) EA010409B1 (pl)
ES (1) ES2285270T3 (pl)
HK (1) HK1087042A1 (pl)
HR (1) HRP20050439B1 (pl)
IL (1) IL168626A (pl)
IS (1) IS2405B (pl)
NO (1) NO326946B1 (pl)
NZ (1) NZ540744A (pl)
PL (1) PL216067B1 (pl)
PT (1) PT1567171E (pl)
SE (1) SE525461C3 (pl)
SI (1) SI1567171T1 (pl)
WO (1) WO2004047848A1 (pl)
ZA (1) ZA200504111B (pl)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2666840C (en) * 2006-10-20 2015-07-14 The Australian National University Inhibition of degradation of extracellular matrix
US20110008343A1 (en) * 2007-06-08 2011-01-13 Lambris John D Method Of Reducing Tissue Loss In Pancreatic Islet Cell Transplantation
CN102917711A (zh) * 2010-03-12 2013-02-06 澳大利亚国立大学 硫酸乙酰肝素替代疗法
WO2012008908A1 (en) * 2010-07-16 2012-01-19 Tx Medic Ab Cell therapy
CN102973592A (zh) * 2012-11-26 2013-03-20 合肥博太医药生物技术发展有限公司 硫酸葡聚糖在制备治疗糖尿病药物中的应用
SE537742C2 (sv) 2013-05-13 2015-10-13 Tx Medic Ab Dextransulfat för cellmobilisering
GB201408233D0 (en) 2014-05-09 2014-06-25 Austrianova Singapore Pte Ltd Use of polyanionic composition
WO2015190989A1 (en) * 2014-06-12 2015-12-17 Tx Medic Ab The use of dextran sulfate having an average molecular weight below 10000 da for inducing angiogenisis in a subject
CN106573012B (zh) 2014-06-12 2020-02-28 Tx医生公司 平均分子量低于10000Da的硫酸葡聚糖用于诱导受试者中的血管新生的用途
SE538503C2 (en) 2014-11-11 2016-08-16 Tx Medic Ab New dextran sulfate
SE539575C2 (en) * 2015-07-30 2017-10-17 Tx Medic Ab Dextran sulfate for use in treating, inhibiting or preventing cardiac fibrosis
CN111263636A (zh) * 2017-09-08 2020-06-09 Tx医生公司 硫酸葡聚糖的新用途
SE544768C2 (en) * 2021-03-24 2022-11-08 Tx Medic Ab Combination for treatment of thromboinflammation

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0240098A3 (en) * 1986-04-04 1989-05-10 Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo Oligo and polysaccharides for the treatment of diseases caused by retroviruses
IL88554A0 (en) * 1988-12-01 1989-07-31 Hadassah Med Org Compositions containing a compound binding to a heparin receptor
TW318142B (pl) 1991-06-03 1997-10-21 Mitsubishi Chemicals Co Ltd
US5464815A (en) 1993-09-08 1995-11-07 Genentech, Inc. Inhibition of heparin-binding
CN1178070A (zh) * 1996-09-27 1998-04-08 刘春江 组织脏器移植用保存溶液·手术等时组织脏器保护溶液
CN1057192C (zh) * 1997-09-10 2000-10-11 上海长征医院 一种配制多器官保存液的方法

Also Published As

Publication number Publication date
CY1106739T1 (el) 2012-05-23
JP4972113B2 (ja) 2012-07-11
US20160136331A1 (en) 2016-05-19
ATE359798T1 (de) 2007-05-15
US20140094435A1 (en) 2014-04-03
HRP20050439B1 (en) 2007-11-30
US8906884B2 (en) 2014-12-09
DE60313356D1 (de) 2007-05-31
BR0316666A (pt) 2005-10-11
KR100828807B1 (ko) 2008-05-09
NO20052505L (no) 2005-06-20
IS7908A (is) 2005-06-23
BRPI0316666B8 (pt) 2021-05-25
CN1296051C (zh) 2007-01-24
PT1567171E (pt) 2007-07-09
PL216067B1 (pl) 2014-02-28
CA2507595C (en) 2011-11-08
US9364499B2 (en) 2016-06-14
SI1567171T1 (sl) 2007-08-31
KR20050089803A (ko) 2005-09-08
EA200500757A1 (ru) 2005-12-29
AU2003302378A1 (en) 2004-06-18
JP2006509057A (ja) 2006-03-16
US8901104B2 (en) 2014-12-02
IL168626A (en) 2011-06-30
PL376302A1 (pl) 2005-12-27
SE0203526D0 (sv) 2002-11-28
JP4315908B2 (ja) 2009-08-19
NZ540744A (en) 2007-02-23
HRP20050439A2 (en) 2005-12-31
HK1087042A1 (en) 2006-10-06
IS2405B (is) 2008-09-15
US10307440B2 (en) 2019-06-04
ZA200504111B (en) 2006-07-26
US8629123B2 (en) 2014-01-14
SE525461C2 (sv) 2005-02-22
BRPI0316666B1 (pt) 2018-09-25
CN1717240A (zh) 2006-01-04
DE60313356T2 (de) 2007-08-16
AU2003302378B2 (en) 2008-02-21
WO2004047848A1 (en) 2004-06-10
ES2285270T3 (es) 2007-11-16
CA2507595A1 (en) 2004-06-10
US20100113389A1 (en) 2010-05-06
US20060111319A1 (en) 2006-05-25
EP1567171A1 (en) 2005-08-31
JP2009167201A (ja) 2009-07-30
SE0203526L (sv) 2004-05-29
EA010409B1 (ru) 2008-08-29
US20140093484A1 (en) 2014-04-03
EP1567171B1 (en) 2007-04-18
NO326946B1 (no) 2009-03-16
DK1567171T3 (da) 2007-07-16

Similar Documents

Publication Publication Date Title
US10307440B2 (en) Use of dextran sulfate
Goto et al. Low molecular weight dextran sulfate prevents the instant blood-mediated inflammatory reaction induced by adult porcine islets
Johansson et al. Low molecular weight dextran sulfate: a strong candidate drug to block IBMIR in clinical islet transplantation
Bennet et al. DAMAGE TO PORCINE ISLETS OF LANGERHANS AFTER EXPOSURE TO HUMAN BLOOD IN VITRO, OR AFTER INTRAPORTAL TRANSPLANTATION TO CYNOMOLOGUS MONKEYS: Protective Effects of sCR1 and Heparin: 1
Goto et al. Dissecting the instant blood‐mediated inflammatory reaction in islet xenotransplantation
Gustafson et al. The instant blood-mediated inflammatory reaction characterized in hepatocyte transplantation
Berman et al. Interference with tissue factor prolongs intrahepatic islet allograft survival in a nonhuman primate marginal mass model
von Zur-Mühlen et al. Open randomized multicenter study to evaluate safety and efficacy of low molecular weight sulfated dextran in islet transplantation
BRPI0923068A2 (pt) uso de composições para tratamento de doenças e distúrbios de pulmão e pulmonares, as referidas composições, e kit
Schmidt et al. Low molecular weight dextran sulfate is well tolerated in humans and increases endogenous expression of islet protective hepatocyte growth factor
WO2020010958A1 (zh) Metrnl蛋白或基因在血管堵塞性疾病中的应用
MXPA05005778A (en) New use of dextran sulfate
US20050255111A1 (en) Use of an inhibitor or antagonist against tissue factor
Johansson Mechanisms and Therapeutic Interventions of Instant Blood-Mediated Inflammatory Reaction (IBMIR)

Legal Events

Date Code Title Description
NUG Patent has lapsed